Akebia Therapeutics, Inc., a bio pharmaceutical company, hsares on the rise propr to the presentation to be given to JMP Securities Life Sciences Conference on Tuesday, June 23 at 3:00 p.m. Eastern Time.
The firm’s major focus is on therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF).
View the full release here.